KalVista Pharmaceuticals, Inc. (KALV) Form 10-Q — May 14, 2026
KalVista Pharmaceuticals reported $40.9 million in total revenue for the first quarter ended March 31, 2026, driven by $39.2 million in product sales of its approved therapy EKTERLY. The company posted a net loss of $23.5 million, or $0.43 per share, as it scales commercial operations for its lead asset in hereditary angioedema. In a subsequent event disclosed in the filing, KalVista entered into a definitive merger agreement with Chiesi Farmaceutici S.p.A. on April 29, 2026.
Key figures
- Revenue
- 40863000
- Termination fee
- 66400000
- Shares outstanding
- 53240888
- Merger price per share
- 27
- Convertible notes principal
- 143750000
- Royalty obligation carrying value
- 129500000
Price after filing
Close on the filing date to close N calendar days later (from $26.76). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.